• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
Recently, researchers published a study entitled “Mutant KRAS-m6A Epitranscriptome Axis Promotes Colorectal Cancer and Is a Therapeutic Target.” The study found thatKRASmutations, which occur in approximately 40%–50% of patients with colorectal cancer (CRC), act as driver mutations that mediate aberrant epitranscriptomic remodeling. In clinical samples from patients with CRC, mutant KRAS was associated with elevated levels of mRNA N6-methyladenosine (m6A) modification. Similarly, m6A levels were significantly increased in mutant KRAS cells and mice compared with their wild-type KRAS counterparts in isogenic CRC cell lines and animal models.
Unexplained recurrent spontaneous abortion (URSA) is a common early-pregnancy disorder that seriously affects reproductive health, yet its pathogenesis remains poorly understood. Recently, researchers published a study entitled “NSUN2-Mediated m5C Modification of TGFB1 in Trophoblasts Remodels Macrophage Function to Prevent URSA.” The study revealed for the first time thatNOP2/Sun RNA methyltransferase 2 (NSUN2), an RNA 5-methylcytosine (m5C) methyltransferase, plays a previously unrecognized role in protecting pregnancy by enabling trophoblasts to regulate macrophage function.
Immune checkpointtherapy has transformed the treatment landscape for solid tumors over the past decade. Inhibitors targetingPD-1,PD-L1, andCTLA-4have enabled some patients with advanced cancer to achieve long-term survival. However, substantial limitations remain: only approximately 20%–30% of patients with solid tumors derive significant clinical benefit from these therapies. Most tumors establish a highly immunosuppressive tumor microenvironment that prevents immune cells from infiltrating the tumor or impairs their cytotoxic activity even after they arrive.
The efficacy of cancer immunotherapy is often compromised by low tumor immunogenicity and an immunosuppressive tumor microenvironment (TME), a phenomenon partly driven by the reprogramming of adenosine metabolism within tumors.
CAR T-celltherapy genetically modifies a patient’s own immune cells to recognize and attack cancer. Although the approach has shown tremendous promise, particularly in blood cancers, its reach remains limited. According to a recent analysis, only about 4% of patients with advanced or metastatic cancer in the United States are currently eligible for CAR T-cell therapy, and closer to 3% are likely to benefit.
WhileChimeric Antigen Receptor (CAR) T-celltherapy has achieved remarkable success in hematologic malignancies, this "living drug" has repeatedly hit a brick wall when confronting solid tumors. Worldwide, tens of millions of people are diagnosed each year with solid malignancies such as lung, gastric, and pancreatic cancers. Pancreatic cancer, for instance, has long stagnated at a 5-year survival rate of around 10%, while mortality rates for ovarian cancer remain grimly high. Within the dense microenvironment of these solid tumors, CAR-T cells face a dual dilemma: they fail to infiltrate, and even when they do manage to enter, they are rapidly rendered dysfunctional.
Recently, a study published in the Journal of Extracellular Vesicles unraveled a previously unknown intercellular communication axis spanning tumors, extracellular vesicles, and platelets. The researchers showed that tumor cells selectively package endogenousdouble-stranded RNA (dsRNA)into extracellular vesicles (EVs), which then activate the innate immune OAS–RNASEL pathway in blood platelets, triggering targeted degradation of ribosomal proteinmRNAs(RP mRNAs).
The clinical success ofchimeric antigen receptor (CAR) T-celltherapy highlights the need for scalable, non-invasive strategies to engineer T cells directly in vivo. AlthoughmRNA deliveryoffers a promising alternative,lipid nanoparticle-based carriersgenerally exhibit limited T-cell transfection efficiency in vivo and often require antibody conjugation.
Evolution is constantly writing new biological innovations within genomes. Exploring this vast design space holds the potential to unlock transformative biotechnology functions; however, even the simplest genomes are immensely complex, where a single nucleotide mutation can render an organism non-viable. Consequently, most advances in biological engineering have remained restricted to individual genes or genetic circuits, while whole-genome-scale de novo design has long been deemed an elusive goal.
Pathological myocardial hypertrophy serves as a critical harbinger of heart failure (HF) and can be triggered by external stimuli such as pressure overload or heightened sympathetic nervous activity. Although liquid-liquid phase separation (LLPS) represents a fundamental cellular stress-response mechanism implicated in diverse disease etiologies, its precise role in heart failure has remained elusive. Of particular interest are paraspeckles—membrane-less nuclear organelles formed via LLPS driven by the long non-coding RNA Neat1.
